Ardelyx, Inc.
General ticker "ARDX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.5B (TTM average)
Ardelyx, Inc. does not follow the US Stock Market performance with the rate: -22.7%.
Estimated limits based on current volatility of 2.5%: low 3.11$, high 3.27$
Factors to consider:
- Earnings expected soon, date: 2026-10-29 amc
- Total employees count: 489 (+23.8%) as of 2025
- US accounted for 92.8% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Cash flow deficits, Manufacturing capacity, Sole source suppliers, CMO retention failure, Liquidity and credit risks
- Current price 27.5% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.26$, 9.00$]
- 2026-12-31 to 2027-12-31 estimated range: [4.56$, 9.48$]
Financial Metrics affecting the ARDX estimates:
- Positive: with PPE of -24.9 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Positive: -13.52 < Operating profit margin, % of -9.14
- Positive: Interest expense per share per price, % of 2.02 <= 2.54
- Positive: Inventory ratio change, % of 0.85 <= 1.34
- Positive: -28.70 < Return on assets ratio (scaled to [-100,100]) of -10.94
- Negative: negative Industry operating income (median)
- Negative: Investing cash flow per share per price, % of -0.64 <= -0.14
Short-term ARDX quotes
Long-term ARDX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $124.46MM | $333.62MM | $407.32MM |
| Operating Expenses | $187.73MM | $361.56MM | $448.30MM |
| Operating Income | $-63.28MM | $-27.95MM | $-40.98MM |
| Non-Operating Income | $-2.24MM | $-10.92MM | $-19.65MM |
| Interest Expense | $8.87MM | $20.09MM | $28.40MM |
| R&D Expense | $35.54MM | $52.32MM | $71.53MM |
| Income(Loss) | $-65.52MM | $-38.87MM | $-60.63MM |
| Taxes | $0.55MM | $0.27MM | $0.97MM |
| Net Income(Loss)* | $-66.07MM | $-39.14MM | $-61.60MM |
| Stockholders Equity | $166.82MM | $173.29MM | $166.95MM |
| Inventory | $12.45MM | $21.17MM | $17.73MM |
| Assets | $297.58MM | $435.75MM | $501.60MM |
| Operating Cash Flow | $-89.72MM | $-44.81MM | $-42.48MM |
| Capital expenditure | $0.34MM | $1.01MM | $1.49MM |
| Investing Cash Flow | $-131.25MM | $-18.32MM | $-8.96MM |
| Financing Cash Flow | $146.29MM | $106.59MM | $54.51MM |
| Earnings Per Share** | $-0.30 | $-0.17 | $-0.26 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.